Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Plasma kallikrein inhibitors
4 evidence topics · 4 sources
Lanadelumab: indication and dosing interval
Berotralstat: oral prophylaxis and dosing
Lanadelumab and berotralstat: guideline summary of efficacy
“Lanadelumab, a fully human monoclonal antibody directed against plasma kallikrein, reduces the risk of attacks in the context of LTP, with a low risk of adverse events and a positive impact on QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reported attack rates with this drug are less than 0.3 per month with biweekly dosing, and over 95% of treatment-emergent adverse events are non-serious.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Berotralstat, an oral plasma kallikrein inhibitor, demonstrated efficacy in a pivotal trial, achieving a ∼50% reduction in attack rate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should be aware of delayed onset of action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote